Starwatch: sanguine Antares contrasts with silver light of the moon
Summer in the UK and similar northern latitudes is the best time of year to catch sight of the zodiacal constellation Scorpius, the scorpion. The constellation contains the beautiful star Antares. Shining blood-red just above the southern horizon, Antares is a prize well worth tracking down and this week, the moon helps point it out.
The chart shows the view looking south from London at 23:00 BST on 9 June. The moon will be cruising through the constellation and Antares will be unmistakable, its sanguine hues contrasting beautifully with the silver light of the Earth's natural satellite.
Technically, the moon will still be in its waxing gibbous phase but with 98% of its visible surface illuminated, in practice it will appear to us as essentially a full moon.
Antares itself is the 15th brightest star in the night sky. Situated about 550 light years from Earth, it contains about 15 times the mass of the sun, is about 680 times the size, and pours out almost 76,000 times more energy.
From the southern hemisphere, around mid-evening, Antares and Scorpius appear high in the eastern sky. From Sydney on 10 June, the moon and Antares will be side by side.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 hours ago
- Medscape
Prevalence of Autoimmune Diseases Rose in UK Pregnancies
Over the past two decades, the prevalence of autoimmune diseases among pregnant women in the UK has significantly increased, with psoriasis being the most common condition. The likelihood of diagnosis varied across sociodemographic factors, including age, ethnicity, and socioeconomic status. METHODOLOGY: Researchers conducted a UK population-based retrospective cohort study using routinely collected primary care data from Clinical Practice Research Datalink Gold and Aurum pregnancy registers. This study included 5,165,960 pregnancies in 2,831,472 women aged 15-49 years from 2000 to 2021, including 185,208 pregnancies in 100,655 women with a coded diagnosis of autoimmune disease. Researchers evaluated the prevalence trend, calculated annually for both overall and each of 17 autoimmune diseases, during pregnancy via diagnostic codes and analysed their associations with sociodemographic factors. TAKEAWAY: The overall prevalence of autoimmune diseases during pregnancy increased from 3.5% in 2000 to 4.7% in 2021; psoriasis was the most prevalent condition, followed by inflammatory bowel disease and rheumatoid arthritis between 2000 and 2010 and type 1 diabetes and inflammatory bowel disease in 2010-2021. The prevalence of most of the autoimmune diseases significantly increased between 2000 and 2021, with the steepest rise observed in Hashimoto's thyroiditis (+6.22%), coeliac disease (+6.20%), and alopecia areata (+4.75%). Women living in less deprived areas had higher odds of autoimmune diseases during pregnancy than those living in more deprived areas (adjusted odds ratio [aOR], 1.10; 95% CI, 1.07-1.14), and Black women had significantly lower odds than White women (aOR, 0.48; 95% CI, 0.45-0.51). Compared with women aged 15-20 years, those aged 21-30 years (aOR, 1.17; 95% CI, 1.14-1.20), 31-40 years (aOR, 1.50; 95% CI, 1.45-1.55), and 41-50 years (aOR, 1.75; 95% CI, 1.68-1.82) had increased odds of being diagnosed with autoimmune disease before pregnancy. IN PRACTICE: "This study gives a clear estimate of the burden of autoimmune diseases in pregnancy in the UK and the possible association with various demographic factors, and will help the process of improving maternity care for women with these health conditions," the authors wrote. SOURCE: This study was led by Megha Singh, PhD, Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, England. It was published online on June 02, 2025, in The Lancet Rheumatology . LIMITATIONS: This study did not include some rare autoimmune diseases like dermatomyositis. Although the use of primary care data reduced entry-level coding biases, improvements in recording practices over time might affect data quality and completeness, potentially affecting observed trends. Additionally, this study may have underestimated the prevalence of autoimmune diseases since most cases are diagnosed and managed in secondary care. DISCLOSURES: This study was supported by the Strategic Priority Fund "Tackling multimorbidity at scale" programme. One author initially worked at the University of Birmingham and later joined AstraZeneca and currently holds an honorary contract with the University of Birmingham.
Yahoo
7 hours ago
- Yahoo
CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development
Extends capabilities of industry-leading PhysioMimix DILI assay for comparative studies between animal species and human Generates deeper insights into inter-species differences to de-risk development pipelines and minimize animal testing CAMBRIDGE, England, June 10, 2025--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal microphysiological system (MPS) models that enhance translatability in preclinical drug safety and toxicology assessments to its Contract Research Services (CRS). Building upon the Company's FDA-recognized drug induced liver injury (DILI) assay, the expanded offering enables rapid, comparative studies between commonly used animal and human models to flag interspecies differences early, and better informs in vivo study design. Traditional human in vitro methods have limited capacity to accurately determine drug toxicity. Added to this, the discrepancies between these methods and in vivo animal studies make it challenging to accurately predict safety risks for humans during preclinical testing. Often, unsafe drug candidates are wrongly progressed, and potentially life-saving ones are misclassified and abandoned, ultimately impacting clinical progression. In response to growing market demand for tools that address these concerns, CN Bio has expanded the in vitro to in vivo extrapolation (IVIVE) capabilities of its established PhysioMimix® DILI assay, adding the ability to easily compare results across human-, rat-, and dog-derived Liver-on-a-chip models. These assays offer a modernized workflow to generate predictive and actionable insights that mitigate the risk of costly, late-stage conflicting data, and reduce unnecessary animal use by providing early warning of hepatotoxicity/DILI prior to in vivo studies. Accessible through the Company's CRS, the new offering harnesses the longstanding expertise of CN Bio's scientific team to provide detailed data analysis, optimized outcomes, and data-driven conclusions beyond what is achievable using existing in vitro models. The assay enables a broad range of longitudinal and endpoint testing for DILI-specific biomarkers from single- or repeat-dosing studies over a 14-day experimental window. This provides a more comprehensive overview of underlying mechanisms of hepatotoxicity or latent effects of drug candidates to improve IVIVE assessment and streamline clinical progression. Dr Emily Richardson, Lead Scientist, Safety and Toxicology, CN Bio, said: "Understanding safety risks is critical to successful drug development, however, fundamental physiological and biological differences between species can lead to inaccuracies in predictions, often causing drug candidates to be wrongfully abandoned as toxic, or worse, mistakenly classified as safe." She added: "Having established our DILI assay as an industry leading option to garner more valuable insights across the development pipeline, we were in an ideal position to expand its capabilities and address this crucial gap in understanding hepatotoxicity using the most commonly used animal models. Partnering with us to utilize this powerful service not only ensures robust and reliable results but also provides access to a team of Organ-on-a-chip experts, who are invested in your success; to de-risk your pipeline and move it forward with confidence." View source version on Contacts Media contact Lily JefferyTel: +44(0)7891477378Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
ANGLE plc Announces Novel Discoveries Into the Biology of Cancer
PARSORTIX SYSTEM enableS novel DISCOVERIES into the biology of cancer Academic and translational research is the driving force behind the pipeline of next generation cancer therapeutics GUILDFORD, SURREY / / June 10, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of three new peer-reviewed publications reporting first-in-class research into the biology of cancer and potential therapeutic targets using the Company's Parsortix system. Tumour cell release during surgery for prostate cancer1Professor Klaus Pantel and researchers from the University Medical Center Hamburg-Eppendorf published an article in the Journal of Experimental & Clinical Cancer Research, investigating tumour cell release into the local tumour vein and peripheral veins during surgery in early-stage prostate cancer patients. The study provides first evidence for substantial release of healthy and cancerous cells into the blood during prostatectomy surgery. This research opens a new avenue for the Parsortix system to study the important and under-investigated biology of tumour cell release during surgery to understand the risk they pose to patients, and for the development of strategies to minimise the spread of cancer. Tumour cell release during surgery for ovarian cancer2Professor John O'Leary and researchers from Trinity College Dublin have published similar findings in the European Journal of Surgical Oncology, investigating CTC enrichment from the local tumour vein and peripheral veins during surgery in rare epithelial ovarian carcinomas. They reported higher yields of CTCs and CTC clusters in the local tumour vein when compared to peripheral veins. The study also reported that CTCs were detected in early-stage patients, highlighting the risk of early tumour cell dissemination driving cancer progression even in the initial stages of disease. Overall, the authors state that assessing tumour cell release during surgery is a novel strategy to study the biology of this rare disease. Mechanical conditioning & metastatic implications3Professor Julie Lang and researchers from the Cleveland Clinic have published an article in Cancers, investigating biomechanical adaptions of cells that are associated with increased metastatic potential in breast cancer patients. They studied the expression of 1004 genes via RNA-sequencing that reflect how cancer cells respond to a stiff extracellular matrix described as a mechanical conditioning score. The Parsortix system was utilised to enrich and harvest CTCs from a metastatic cohort of breast cancer patients for analysis and compared these to primary and metastatic tissue. The study analysed RNA from CTCs rather than ctDNA to provide insight into gene expression. They state that: 'When analyzing shed ctDNA, there is no insight into gene expression, but rather only the presence of tumor-specific mutations, which is not directly reflective of dynamic tumor gene expression. In fact, only a very small percentage of DNA mutations are expressed, which is why circulating tumor DNA and RNA from CTCs are not parallel assays'. The study reported that the mechanical conditioning score increases progressively through the metastatic cascade (from the primary tumour to CTCs to the metastatic site) and is associated with increased metastatic potential. These are new insights into the biology of metastatic progression and may guide treatment selection with anti-fibrotic drugs. Overall, these publications further underscore the role of the Parsortix system in helping to advance our understanding of the biology of cancer which will ultimately advance oncology drug discovery and development. Already ANGLE's technology has enabled breakthrough research in a number of areas including the metastatic potential of CTC clusters, new potential biomarkers and a novel drug class. Academic and translational research discoveries made possible by the Parsortix system, have the potential to feed the pipeline of next generation personalised cancer diagnostics and therapeutics, as pharma companies increasingly collaborate with academia4. ANGLE's Chief Scientific Officer, Karen Miller, commented:"We are proud to see ANGLE's technology increasingly being exploited to make novel discoveries into the biology of cancer, which may eventually result in new treatment strategies. With advancing analytical capabilities beginning to realise the vast potential of the circulating tumour cell for its wealth of multiomic information, this contribution to the oncology pipeline will continue to grow. We congratulate these key opinion leaders on their outstanding work, and we look forward to more exciting discoveries in the future." 1. Emurlai, G. et al. Comparative analysis of circulating tumor cells in prostatic plexus and peripheral blood of patients undergoing prostatectomy. J. Exp. Clin. Cancer Res. 44, 143 (2025). 2. Lewis, F. et al. A pilot study evaluating the feasibility of enriching and detecting circulating tumour cells from peripheral and ovarian veins in rare epithelial ovarian carcinomas. Eur. J. Surg. Oncol. 51, (2025). 3. Mouneimne, G. et al. Mechanical Conditioning (MeCo) Score Progressively Increases Through the Metastatic Cascade in Breast Cancer via Circulating Tumor Cells. Cancers 17, 1632 (2025). 4. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Research Use Only. Not for use in diagnostic procedures. For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
